Home > Insider Trading > Filing (0000899243-15-002782)

Filing Details

Accession Number:: 0000899243-15-002782
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-08-11 11:46:16
Reporting Period:: 2015-08-11

Filing Date:: 2015-08-11
Accepted Time:: 2015-08-11 11:46:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	Pharmaceutical Preparations (2834)	452748244

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1581754	B. James Tananbaum	3052 Pacific Avenue San Francisco CA 94115	No	No	Yes	No
1594912	Foresite Capital Management Ii, Llc	101 California Street Suite 4100 San Francisco CA 94111	No	No	Yes	No
1594914	Foresite Capital Fund Ii, L.p.	101 California Street Suite 4100 San Francisco CA 94111	No	No	Yes	No
1645157	Foresite Capital Management Iii, Llc	101 California Street Suite 4100 San Francisco CA 94111	No	No	Yes	No
1645158	Foresite Capital Fund Iii, L.p.	101 California Street Suite 4100 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	3,775,400	$0.00	3,775,400	No	4	C	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	312,500	$16.00	4,087,900	No	4	P	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	312,500	$16.00	312,500	No	4	P	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Acquisiton	2015-08-11	17,035	$20.50	329,535	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-08-11	3,775,400	$0.00	3,775,400	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.
Shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the Designated Filer and general partner of FCF II, may be deemed to have the sole voting and dispositive power over these shares. James Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have the sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
FCF II purchased an additional 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of $16.00 per share.
FCF III purchased 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of $16.00 per share.
Shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have the sole voting and dispositive power over these shares. James Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have the sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
The Series B Convertible Preferred Stock has no expiration date.